硼替佐米与地塞米松治疗多发性骨髓瘤：谷草转氨酶（AST）和乳酸脱氢酶（LDH）水平升高与总生存期预后较差相关。
Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival.
作者信息
Kiba Takayoshi, Ito Takuo, Nakashima Toshihisa, Okikawa Yoshiko, Kido Miki, Kimura Akiko, Kameda Keita, Miyamae Fumiaki, Tanaka Suzuko, Atsumi Misao, Sumitani Yoko, Shitakubo Yoshimi, Niimi Hiromasa
机构信息
Division of Modern Medical Technology, Institute for Clinical Research, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, 3-1, Aoyama-cho, Kure-shi, Hiroshima 737-0023, Japan.
出版信息
BMC Cancer. 2014 Jun 21;14:462. doi: 10.1186/1471-2407-14-462.
BACKGROUND
Bortezomib offers a novel approach to the treatment of multiple myeloma producing rapid control. The aim of this study was to investigate the outcomes of bortezomib and dexamethasone-treated patients with multiple myeloma.
METHODS
We conducted a retrospective study of 44 consecutively-treated multiple myeloma patients with bortezomib (1.3 mg/m(2) on days 1, 4, 8, and 11 of a 21-day cycle or 1.3 mg/m(2) intravenously 1, 8, 15, and 22 of every 35-day cycle) and dexamethasone.
RESULTS
The median time to progression, progression free survival time, and overall survival time in the treatment groups was 14.9, 14.9, and 38.3 months, respectively. The present study also suggests the possibility that the prognosis of patients with high levels of AST and LDH might be worse.
CONCLUSIONS
Our results indicate that the treatment of multiple myeloma with bortezomib and dexamethasone is feasible.
背景
硼替佐米为多发性骨髓瘤的治疗提供了一种能实现快速控制的新方法。本研究旨在调查接受硼替佐米和地塞米松治疗的多发性骨髓瘤患者的治疗结果。
方法
我们对44例连续接受硼替佐米（21天周期的第1、4、8和11天给予1.3mg/m²或每35天周期的第1、8、15和22天静脉注射1.3mg/m²）和地塞米松治疗的多发性骨髓瘤患者进行了一项回顾性研究。
结果
治疗组的中位进展时间、无进展生存时间和总生存时间分别为14.9个月、14.9个月和38.3个月。本研究还提示，天冬氨酸转氨酶（AST）和乳酸脱氢酶（LDH）水平高的患者预后可能更差。
结论
我们的结果表明，硼替佐米和地塞米松治疗多发性骨髓瘤是可行的。
Zotero 插件